Skip to main content

Advertisement

SpringerLink
Log in

Newer Antiepileptic Drugs: Evidence Based Use

  • Review Article
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Several new antiepileptic drugs (AED’s) have been approved by the FDA in the last 2 decades. The newer AED’s score over the older ones, in terms of improved tolerability, safety, improved pharmacokinetics and lower drug-drug interactions. However, efficacy may not be significantly higher. This article reviews the newer antiepileptics approved in the pediatric age group and the evidence for or against their clinical use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

ESL:

Eslicarbazepine

FBM:

Felbamate

GABA:

γ-aminobutyric acid

GBP:

Gabapentin

LGS:

Lennox Gastaut syndrome

LCM:

Lacosamide

LEV:

Levetiracetam

LTG:

Lamotrigine

NMDA:

N-Methyl-D-Aspartate

OXC:

Oxcarbazepine

PB:

Phenobarbitone

PGB:

Pregabalin

PHT:

Phenytoin

RFM:

Rufinamide

STP:

Stiripentol

TPM:

Topiramate

TGB:

Tiagabine

VGB:

Vigabatrin

VPA:

Valparin

ZNS:

Zonisamide

References

  1. Sirven JI, Katherine N, Matthew H, Joseph D. Antiepileptic drugs 2012: Recent advances and trends. Mayo Clin Proc. 2012;87:879–89.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  2. Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia. 2010;51:7–26.

    Article  PubMed  CAS  Google Scholar 

  3. Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess. 2005;9:1–157.

    PubMed  CAS  Google Scholar 

  4. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al; SANAD study group. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1016–26.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, et al; Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010;362:790–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  6. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, lvia¨inen RK, et al. ILAE Subcommission on AED Guidelines. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54:551–63.

    Article  PubMed  CAS  Google Scholar 

  7. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al; SANAD study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1000–15.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  8. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ. Levetiracetam monotherapy study group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68:402–8.

    Article  PubMed  CAS  Google Scholar 

  9. Arya R, Glauser TA. Pharmacotherapy of focal epilepsy in children: a systematic review of approved agents. CNS Drugs. 2013;27:273–86.

    Article  PubMed  CAS  Google Scholar 

  10. Guerreiro MM, Vigonius U, Pohlmann H, de Manreza ML, Fejerman N, Antoniuk SA, et al. A double blind controlled clinical trial of oxcarbazepine versus phenytoein in children and adolescents with epilepsy. Epilepsy Res. 1997;27:205–13.

    Article  PubMed  CAS  Google Scholar 

  11. Castillo S, Schmidt DB, White S. Oxcarbazepine add on for drug resistant epilepsy. Cochrane Database Syst Rev. 2000;3:CD002028.

  12. Beydoun A, Sachdeo RC, Kutluay E, McCague K, D’Souza J. Sustained efficacy and lon-term safety of oxcarbazepine: one year open-label extension of study in refractory partial epilepsy. Epilepsia. 2003;44:1160–5.

    Article  PubMed  CAS  Google Scholar 

  13. Vigevano F. Levetiracetam in pediatrics. J Child Neurol. 2005;20:87–93.

    Article  PubMed  Google Scholar 

  14. Schiemann-Delgado J, Yang H, Loge Cde L, Stalvey TJ, Jones J, Legoff D, et al. A long-term open-label extension study assessing cognition and behavior, tolerability, safety, and efficacy of adjunctive levetiracetam in children aged 4 to 16 years with partial-onset seizures. J Child Neurol. 2012;27:80–9.

    Article  PubMed  Google Scholar 

  15. Kossoff EH, Bergey GK, Freeman JM, Vining EP. Levetaricetam psychosis in children with epilepsy. Epilepsia. 2001;42:1611–3.

    Article  PubMed  CAS  Google Scholar 

  16. Obeid M, Pong AW. Efficacy and tolerability of high oral doses of levetiracetam in children with epilepsy. Epilepsy Res. 2010;91:101–5.

    Article  PubMed  CAS  Google Scholar 

  17. Glauser TA, Ayala R, Elterman RD, Mitchell WG, Van Orman CB, Gauer LJ, et al; N159 Study Group. Double blind placebo controlled trial of adjunctive levatiracetam in pediatric partial epilepsy. Neurology. 2006;66:1654–60.

    Article  PubMed  CAS  Google Scholar 

  18. Glauser TA, Pellock JM, Bebin EM, Fountain NB, Ritter FJ, Jensen CM, et al. Efficacy and safety of levatiracetam in children with partial epilepsy: an open label trial. Epilepsia. 2002;43:518–24.

    Article  PubMed  CAS  Google Scholar 

  19. Khan O, Chan E, Cipriani C, Wright C, Crisp E, Kirmani B. Use of intravenous levetiracetam for management of acute seizures in neonates. Pediatr Neurol. 2011;44:265–9.

    Article  PubMed  Google Scholar 

  20. Kirmani BF, Crisp ED, Kalyani S, Rajab H. Role of intravenous levetiracetam in acute seizure management of children. Pediatr Neurol. 2009;41:37–9.

    Article  PubMed  Google Scholar 

  21. Gallantine WB, Hunnicutt AS, Husain AM. Levetiracetam in children with refractory status epilepticus. Epilepsy Behav. 2009;14:215–8.

  22. Borggraefe I, Bonfert M, Bast T, Neubauer BA, Schotten JK, Maßmann K, et al; German HEAD Study Group. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). Eur J Paediatr Neurol. 2013;17:507–14.

    Article  PubMed  Google Scholar 

  23. Akyildiz BN, Kumandaş S. Treatment of pediatric refractory status epilepticus with topiramate. Childs Nerv Syst. 2011;27:1425–30.

    Article  PubMed  Google Scholar 

  24. Glass HC, Poulin C, Shevell MI. Topiramate for the treatment of neonatal seizures. Pediatr Neurol. 2011;44:439–42.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Hosain SA, Merchant S, Solomon GE, Chutorian A. Topiramate for the treatment of infantile spasms. J Child Neurol. 2006;21:17–9.

    Article  PubMed  Google Scholar 

  26. Mohamed K, Appleton R, Rosenbloom L. Efficacy and tolerability of topiramate in childhood and adolescent epilepsy: a clinical experience. Seizure. 2000;9:137–41.

    Article  PubMed  CAS  Google Scholar 

  27. Elterman RD, Glausert TA, Wyllie E, Reife R, Wu SC, Pedger G; Topiramate YP Study Group. A double-blind randomized trial as adjunctive therapy for partial onset seizures in children. Neurology. 1999;52:1338–44.

    Article  PubMed  CAS  Google Scholar 

  28. Sachdeo RC, Galuser TA, Ritter F, Reife R, Lim P, Pledger G; Topiramate YL Study Group. A double-blind randomized trail of topiramate in lennox-gastaut syndrome. Neurology. 1999;52:1882–7.

    Article  PubMed  CAS  Google Scholar 

  29. Kayani S, Sirsi D. The safety and tolerability of newer antiepileptic drugs in children and adolescents. J Cent Nerv Syst Dis. 2012;4:51–63.

    PubMed  CAS  PubMed Central  Google Scholar 

  30. Culy CR, Goa KL. Lamotrigine. A review of its use in childhood epilepsy. Paediatr Drugs. 2000;2:299–330.

    Article  PubMed  CAS  Google Scholar 

  31. Cardenas JF, Rho JM, Ng YT. Reversible lamotrigine-induced neurobehavioral disturbances in children with epilepsy. J Child Neurol. 2010;25:182–7.

    Article  PubMed  Google Scholar 

  32. Gilman JT, West K. A practical guide to AED pharmacology. In: Duchowny M, Cross JH, Arzimanoglou A, editors. Pediatric Epilepsy. New Delhi: Tata Mc Graw-Hill; 2013. p. 406–12.

  33. Leahy JT, Chu-Shore CJ, Fisher JL. Clobazam as an adjunctive therapy in treating seizures associated with lennox–gastaut. Neuropsychiatr Dis Treat. 2011;7:673–81.

    PubMed  CAS  PubMed Central  Google Scholar 

  34. Ng YT, Conry JA, Drummond R, Stolle J, Weinberg MA. Randomized, phase III study results of clobazam in lennox-gastaut syndrome. Neurology. 2011;77:1473–81. doi:10.1212/WNL.0b013e318232de76.

    Article  PubMed  CAS  Google Scholar 

  35. Lawden MC, Eke T, Degg C, Harding GF, Wild JM. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry. 1999;67:716–22.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  36. Conway M, Cubbidge RP, Hosking SL. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia. 2008;49:108–16.

    Article  PubMed  Google Scholar 

  37. Faulkner MA, Tolman JA. Safety and efficacy of vigabatrin for the treatment of infantile spasms. J Cent Nerv Syst Dis. 2011;3:199–207.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  38. Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, et al; United Kingdom Infantile Spasms Study. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 mo: a multicentre randomised trial. Lancet Neurol. 2005;4:712–7.

  39. Elterman RD, Shields WD, Mansfield KA, Nakagawa J; US Infantile Spasms Vigabatrin Study Group. Randomized trial of vigabatrin in patients with infantile spasms. Neurology. 2001;57:1416–21.

  40. Chiron C, Dumas C, Jambaqué I, Mumford J, Dulac O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res. 1997;26:389–95.

    Article  PubMed  CAS  Google Scholar 

  41. Tan HJ, Martland TR, Appleton RE, Kneen R. Effectiveness and tolerability of zonisamide in children with epilepsy: a retrospective review. Seizure. 2000;19:31–5.

    Article  Google Scholar 

  42. Wilfong AA, Willmore LJ. Zonisamide – a review of experience and use in partial seizures. Neuropsychiatr Dis Treat. 2006;2:269–80.

  43. Faught E, Ayala R, Montouris GG, Leppik IE. Zonisamide 922 trial group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology. 2001;57:1774–9.

  44. French J, Smith M, Faught E, Brown L. Practice advisory: The use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 1999;52:1540–5.

  45. Coppola G. Update on rufinamide in childhood epilepsy. Neuropsychiatr Dis Treat. 2011;7:399–407.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  46. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with lennox-gastaut syndrome. Neurology. 2008;70:1950–8.

  47. Olson HE, Loddenkemper T, Vendrame M, Poduri A, Takeoka M, Bergin AM, et al. Rufinamide for the treatment of epileptic spasms. Epilepsy Behav. 2011;20:344–8.

  48. Coppola G, Grosso S, Franzoni E, Veggiotti P, Zamponi N, Parisi P, et al. Rufinamide in refractory childhood epileptic encephalopathies other than lennox-gastaut sindrome. Eur J Neurol. 2011;18:246–51.

  49. Chiron C, Marchand MC, Tran A, Rey E, d’Athis P, Vincent J, et al; STILCO Study Group. Stiripentol in severe myoclonic epilepsy in infancy: a randomized placebo-controlled syndrome-dedicated trial. Lancet. 2000;356:1638–42.

Download references

Conflict of Interest

None.

Source of Funding

None.

Author information

Authors and Affiliations

  1. Department of Pediatrics, Choithram Hospital & Research Centre, Indore, Madhya Pradesh, India

    Gouri Rao Passi

  2. 139, Utkarsh Apartments, Indrapuri Colony, Indore, 452001, India

    Gouri Rao Passi

Authors
  1. Gouri Rao Passi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gouri Rao Passi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Passi, G.R. Newer Antiepileptic Drugs: Evidence Based Use. Indian J Pediatr 81, 1042–1051 (2014). https://doi.org/10.1007/s12098-014-1494-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12098-014-1494-4

Keywords

Search

Navigation